Villacrusis, Angelie T.

HRN: 21-77-76  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/20/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
09/20/2022
09/27/2022
IVT
500mg
Q8
Intestinal Amoebiasis
Waiting Final Action 
09/20/2022
CEFUROXIME 500MG (TAB)
09/20/2022
09/27/2022
ORAL
500mg
Q12
UTI
Waiting Final Action 
10/23/2022
CEFUROXIME 500MG (TAB)
10/23/2022
10/23/2022
ORAL
500mg
BID
Thickly Meconium AF
Waiting Final Action 
10/23/2022
METRONIDAZOLE 500MG (TAB)
10/23/2022
10/29/2022
ORAL
500mg
Tid
Thickly Meconium AF
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: